These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 33560486)
1. Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. Duggan B; Smith A; Barry M Int J Clin Pharm; 2021 Oct; 43(5):1251-1256. PubMed ID: 33560486 [TBL] [Abstract][Full Text] [Related]
2. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. Crosby M; Tadrous M; Gomes T Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249 [TBL] [Abstract][Full Text] [Related]
3. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Aladul MI; Fitzpatrick RW; Chapman SR Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834 [TBL] [Abstract][Full Text] [Related]
4. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals. Jarrion Q; Azzouz B; Robinson J; Jolly D; Vallet C; Trenque T Therapie; 2022; 77(4):467-475. PubMed ID: 35027238 [TBL] [Abstract][Full Text] [Related]
5. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products]. Berreur B; Guerin F; Christophe B; Limido G; Paubel P Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236 [TBL] [Abstract][Full Text] [Related]
6. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153 [TBL] [Abstract][Full Text] [Related]
7. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. Aladul MI; Fitzpatrick RW; Chapman SR BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626 [TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187 [TBL] [Abstract][Full Text] [Related]
9. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea. Cho SK; Jung SY; Kim H; Song YJ; Lee K; Sung YK J Korean Med Sci; 2021 May; 36(20):e143. PubMed ID: 34032032 [TBL] [Abstract][Full Text] [Related]
10. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. Jourdain H; Hoisnard L; Sbidian E; Zureik M RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213 [TBL] [Abstract][Full Text] [Related]
11. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117 [TBL] [Abstract][Full Text] [Related]
12. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785 [No Abstract] [Full Text] [Related]
13. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663 [TBL] [Abstract][Full Text] [Related]
15. Cost to Medicare of Delayed Adalimumab Biosimilar Availability. Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566 [TBL] [Abstract][Full Text] [Related]
16. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting. Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206 [TBL] [Abstract][Full Text] [Related]
17. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective. Clarke K; Ainslie-Garcia M; Ferko N; Shastri K J Med Econ; 2024; 27(1):952-962. PubMed ID: 39015093 [TBL] [Abstract][Full Text] [Related]
18. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. Barker J; Girolomoni G; Egeberg A; Goncalves J; Pieper B; Kang T J Dermatolog Treat; 2020 Dec; 31(8):794-800. PubMed ID: 31094242 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. Lu X; Hu R; Peng L; Liu M; Sun Z Front Immunol; 2021; 12():638444. PubMed ID: 33889152 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]